New York, NY (USA), October 24, 2012 – Castle Surgical, Inc. announced today that its Chief Executive Officer, Paras Patani, will deliver the keynote address at “Opportunities for Collaboration”, a networking event for Israeli-based medical device companies. The address, titled “The Future of Kidney Cancer Surgery: The Changing Standard of Care for Renal Cell Carcinoma”, will be presented at the Offices of Hodgson Russ LLP in Manhattan on Thursday, October 25th. Castle Surgical is a surgical devices company dedicated to promoting the use of partial nephrectomy and addressing the needs of the $800 million kidney cancer surgery market.
Castle Surgical has developed a line of open and laparoscopic surgical instruments that greatly simplify the partial nephrectomy surgical procedure. The company’s patent-pending technologies offer the potential to improve patient clinical outcomes, reduce the risk of surgical complications, and lower treatment costs for kidney cancer surgery by 85% vs. the current standard of care.1
Partial nephrectomy, in which only the cancerous tumor is excised and most of the patient’s original kidney is left intact, is a vastly underutilized surgical option for treating kidney cancer. Although the procedure is advocated by the American Urologic Association (AUA) and the European Association of Urology (EAU) “whenever possible”, partial kidney removal is performed in only 20% of cancer operations today.2,3 In most cases, patients lose their entire kidney, called radical nephrectomy, even though most of the kidney tissue is still viable and healthy. Furthermore, patients undergoing radical nephrectomy have a 38% higher risk of mortality from all causes and are 1.4 times more likely to experience a heart attack or stroke than those treated by partial nephrectomy instead.4 Radical nephrectomy patients are also more likely
Read complete article:
- Posted in: kidney cancer